Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma

EBV‐positive nodal low‐grade B‐cell lymphoma with BCL3, IgA and IRTA1 expression: Is this a polymorphic lymphoproliferative disorder or an EBV‐positive nodal marginal zone lymphoma?

“…Moreover, the tumor cells were positive for IRTA1, which is a useful diagnostic marker for marginal zone lymphoma (MZL), including NMZL. 4 Additionally, common IgA expression has been reported in a subset of MZL, including EBVpositive EMZL, which was also elevated in the serum of our patient. 1 Lastly, the BCL3 translocation confirmed in our case has been reported in other cases of MZL.…”

“…However, the present case was different from conventional polymorphic LPD regarding the diffuse EBER positivity and monomorphic morphology. Moreover, the tumor cells were positive for IRTA1, which is a useful diagnostic marker for marginal zone lymphoma (MZL), including NMZL . Additionally, common IgA expression has been reported in a subset of MZL, including EBV‐positive EMZL, which was also elevated in the serum of our patient .…”

Pathology of nodal marginal zone lymphomas

“…Immunoglobulin superfamily receptor translocation-associated-1 (IRTA-1) has been restricted to MALT and NMZL in about 70-90% of cases [24]; these figures have been substantially confirmed by an independent study utilizing a different clone [28]. IgD is usually negative, but those cases that display IgD positivity mimic splenic MZL and are therefore defined as 'splenic-type' NMZL [12].…”

Evaluation of CD307a expression patterns during normal B‐cell maturation and in B‐cell malignancies by flow cytometry

“…It is important to highlight that, in the present study, a small number of MZL cases were analyzed, and all of them showed absence of CD5 expression. Incidentally, a novel immunophenotypic marker for MZL has been recently discovered: CD307d expression was significantly associated with nodal and extranodal MZL with high specificity, being a good candidate marker for MZL diagnosis by flow cytometry (7,33).…”